Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women

P. L. Selby, Munro Peacock

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones. To assess the effect of these sex steroids in patients with primary hyperparathyroidism, we treated postmenopausal women who had hyperparathyroidism with either ethinyl estradiol (n = 6) or norethindrone (n = 11). After three weeks of treatment, the bone-turnover rate declined and plasma calcium fell from a mean (± 1 SE) of 2.77 ± 0.07 mmol per liter (11.1 ± 0.3 mg per deciliter) to 2.58 ± 0.05 mmol per liter (10.3 ± 0.2 mg per deciliter; P <0.01) in the group treated with ethinyl estradiol, and from 2.93 ± 0.08 mmol per liter (11.7 ± 0.3 mg per deciliter) to 2.84 ± 0.08 mmol per liter (11.4 ± 0.3 per deciliter; P <0.05) in the patients who received norethindrone. No significant changes in the plasma levels of parathyroid hormone, calcitonin, or calcitriol were observed after the estrogen-induced increases in vitamin D-binding protein had been taken into account. Since the decline in plasma calcium levels did not stimulate secretion of parathyroid hormone, we conclude that treatment with either sex steroid resets the threshold for secretion of parathyroid hormone. Thus, although the reductions in plasma calcium levels were moderate, sex-hormone therapy may be useful in the treatment of mild hyperparathyroidism in postmenopausal women.

Original languageEnglish (US)
Pages (from-to)1481-1485
Number of pages5
JournalNew England Journal of Medicine
Volume314
Issue number23
StatePublished - 1986
Externally publishedYes

Fingerprint

Norethindrone
Ethinyl Estradiol
Primary Hyperparathyroidism
Calcium
Parathyroid Hormone
Hyperparathyroidism
Bone Remodeling
Steroids
Vitamin D-Binding Protein
Therapeutics
Calcitriol
Calcitonin
Gonadal Steroid Hormones
Estrogens
Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. / Selby, P. L.; Peacock, Munro.

In: New England Journal of Medicine, Vol. 314, No. 23, 1986, p. 1481-1485.

Research output: Contribution to journalArticle

@article{1c9ce6a55c5a4d93b489bce0b22bc7e0,
title = "Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women",
abstract = "Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones. To assess the effect of these sex steroids in patients with primary hyperparathyroidism, we treated postmenopausal women who had hyperparathyroidism with either ethinyl estradiol (n = 6) or norethindrone (n = 11). After three weeks of treatment, the bone-turnover rate declined and plasma calcium fell from a mean (± 1 SE) of 2.77 ± 0.07 mmol per liter (11.1 ± 0.3 mg per deciliter) to 2.58 ± 0.05 mmol per liter (10.3 ± 0.2 mg per deciliter; P <0.01) in the group treated with ethinyl estradiol, and from 2.93 ± 0.08 mmol per liter (11.7 ± 0.3 mg per deciliter) to 2.84 ± 0.08 mmol per liter (11.4 ± 0.3 per deciliter; P <0.05) in the patients who received norethindrone. No significant changes in the plasma levels of parathyroid hormone, calcitonin, or calcitriol were observed after the estrogen-induced increases in vitamin D-binding protein had been taken into account. Since the decline in plasma calcium levels did not stimulate secretion of parathyroid hormone, we conclude that treatment with either sex steroid resets the threshold for secretion of parathyroid hormone. Thus, although the reductions in plasma calcium levels were moderate, sex-hormone therapy may be useful in the treatment of mild hyperparathyroidism in postmenopausal women.",
author = "Selby, {P. L.} and Munro Peacock",
year = "1986",
language = "English (US)",
volume = "314",
pages = "1481--1485",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women

AU - Selby, P. L.

AU - Peacock, Munro

PY - 1986

Y1 - 1986

N2 - Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones. To assess the effect of these sex steroids in patients with primary hyperparathyroidism, we treated postmenopausal women who had hyperparathyroidism with either ethinyl estradiol (n = 6) or norethindrone (n = 11). After three weeks of treatment, the bone-turnover rate declined and plasma calcium fell from a mean (± 1 SE) of 2.77 ± 0.07 mmol per liter (11.1 ± 0.3 mg per deciliter) to 2.58 ± 0.05 mmol per liter (10.3 ± 0.2 mg per deciliter; P <0.01) in the group treated with ethinyl estradiol, and from 2.93 ± 0.08 mmol per liter (11.7 ± 0.3 mg per deciliter) to 2.84 ± 0.08 mmol per liter (11.4 ± 0.3 per deciliter; P <0.05) in the patients who received norethindrone. No significant changes in the plasma levels of parathyroid hormone, calcitonin, or calcitriol were observed after the estrogen-induced increases in vitamin D-binding protein had been taken into account. Since the decline in plasma calcium levels did not stimulate secretion of parathyroid hormone, we conclude that treatment with either sex steroid resets the threshold for secretion of parathyroid hormone. Thus, although the reductions in plasma calcium levels were moderate, sex-hormone therapy may be useful in the treatment of mild hyperparathyroidism in postmenopausal women.

AB - Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones. To assess the effect of these sex steroids in patients with primary hyperparathyroidism, we treated postmenopausal women who had hyperparathyroidism with either ethinyl estradiol (n = 6) or norethindrone (n = 11). After three weeks of treatment, the bone-turnover rate declined and plasma calcium fell from a mean (± 1 SE) of 2.77 ± 0.07 mmol per liter (11.1 ± 0.3 mg per deciliter) to 2.58 ± 0.05 mmol per liter (10.3 ± 0.2 mg per deciliter; P <0.01) in the group treated with ethinyl estradiol, and from 2.93 ± 0.08 mmol per liter (11.7 ± 0.3 mg per deciliter) to 2.84 ± 0.08 mmol per liter (11.4 ± 0.3 per deciliter; P <0.05) in the patients who received norethindrone. No significant changes in the plasma levels of parathyroid hormone, calcitonin, or calcitriol were observed after the estrogen-induced increases in vitamin D-binding protein had been taken into account. Since the decline in plasma calcium levels did not stimulate secretion of parathyroid hormone, we conclude that treatment with either sex steroid resets the threshold for secretion of parathyroid hormone. Thus, although the reductions in plasma calcium levels were moderate, sex-hormone therapy may be useful in the treatment of mild hyperparathyroidism in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=0022651390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022651390&partnerID=8YFLogxK

M3 - Article

VL - 314

SP - 1481

EP - 1485

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -